• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一项针对现实生活中精神分裂症患者CYP1A2基因多态性的奥氮平血药浓度的6年回顾性研究。

A 6-year retrospective study of olanzapine plasma concentration inpatients with schizophrenia CYP1A2 polymorphisms in real-life settings.

作者信息

Zhang Yan, Sun Lisha, Su Yanli, Wang Hui

机构信息

Xi'an Mental Health Center, 710100, Xi'an, Shaanxi, PR China.

Xi'an Key Laboratory of Pharmacy (Mental Health), 710100, Xi'an, Shaanxi, PR China.

出版信息

Heliyon. 2024 Oct 18;10(20):e39367. doi: 10.1016/j.heliyon.2024.e39367. eCollection 2024 Oct 30.

DOI:10.1016/j.heliyon.2024.e39367
PMID:39498058
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11532838/
Abstract

AIM

to investigate the potential influence of CYP1A2 polymorphisms on olanzapine plasma concentration of inpatients with schizophrenia in real-life settings.

METHODS

409 inpatients who received OLA for at least 2 weeks, from June 2016 to March 2022 were included in the retrospective investigation. Moreover, 503 samples of above inpatients receiving OLA was built to investigate the influence of the relevant OLA plasma concentration, polymorphisms CYP1A2 -163C/A on the inpatients outcome.

RESULTS

Scale score reduction rate (SSRR) in 1 mutated CYP1A2 -163C/A alleles (CA) was significantly higher than other CYP1A2 alleles (CC + AA) (P = 0.002). Inverse S-curve correlations relationship was between SSRR and plasma concentrations of OLA (r = 0.130, P < 0.005). When remove ineffective subjects (ineffective group), the results of all CYP1A2 -163C/A genotype showed perfect correlations relationship tendencies with SSRR (r = 1.000). The best concentrations of OLA corrected for daily dose (C/D) range and the best concentration range of OLA of all CYP1A2 -163C/A genotype was 3.18-3.53 ng/mL/mg and 17.42-57.33 ng/mL. The C/D range and concentration range of OLA were 2.722-4.221 ng/mL/mg and 13.61-84.42 ng/mL, which belong CYP1A2 -163C/A CA genotype subjects, was largest.

CONCLUSIONS

The best effective C/D range and concentration range of OLA respective were 3.18-3.53 ng/mL/mg and 17.42-57.33 ng/mL, which range values of CYP1A2 -163C/A CA genotype of inpatients with schizophrenia was largest.

摘要

目的

探讨CYP1A2基因多态性对现实生活中精神分裂症住院患者奥氮平血药浓度的潜在影响。

方法

纳入2016年6月至2022年3月期间接受奥氮平治疗至少2周的409例住院患者进行回顾性研究。此外，构建503例上述接受奥氮平治疗的住院患者样本，以研究相关奥氮平血药浓度、CYP1A2 -163C/A基因多态性对住院患者结局的影响。

结果

1个CYP1A2 -163C/A等位基因突变（CA）的量表评分降低率（SSRR）显著高于其他CYP1A2等位基因（CC + AA）（P = 0.002）。SSRR与奥氮平血药浓度呈反向S曲线相关关系（r = 0.130，P < 0.005）。剔除无效受试者（无效组）后，所有CYP1A2 -163C/A基因型结果与SSRR均呈现出完美的相关关系趋势（r = 1.000）。所有CYP1A2 -163C/A基因型奥氮平校正日剂量后的最佳血药浓度（C/D）范围和最佳血药浓度范围分别为3.18 - 3.53 ng/mL/mg和17.42 - 57.33 ng/mL。属于CYP1A2 -163C/A CA基因型受试者的奥氮平C/D范围和血药浓度范围分别为2.722 - 4.221 ng/mL/mg和13.61 - 84.42 ng/mL，为最大。

结论

奥氮平最佳有效C/D范围和血药浓度范围分别为3.18 - 3.53 ng/mL/mg和17.42 - 57.33 ng/mL，其中精神分裂症住院患者CYP1A2 -163C/A CA基因型的范围值最大。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22a1/11532838/80937b4b3c0e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22a1/11532838/b2b9a37ee3a2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22a1/11532838/b26cad17b459/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22a1/11532838/80937b4b3c0e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22a1/11532838/b2b9a37ee3a2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22a1/11532838/b26cad17b459/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22a1/11532838/80937b4b3c0e/gr3.jpg

相似文献

1
A 6-year retrospective study of olanzapine plasma concentration inpatients with schizophrenia CYP1A2 polymorphisms in real-life settings.一项针对现实生活中精神分裂症患者CYP1A2基因多态性的奥氮平血药浓度的6年回顾性研究。
Heliyon. 2024 Oct 18;10(20):e39367. doi: 10.1016/j.heliyon.2024.e39367. eCollection 2024 Oct 30.
2
CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.CYP1A2*1D和*1F基因多态性对奥氮平的血清浓度有显著影响。
Ther Drug Monit. 2015 Apr;37(2):152-60. doi: 10.1097/FTD.0000000000000119.
3
High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.精神分裂症或分裂情感性障碍患者服用奥氮平作为唯一抗精神病药物时，血清和脑脊液中奥氮平浓度具有高度相关性。
J Clin Psychopharmacol. 2011 Feb;31(1):4-9. doi: 10.1097/JCP.0b013e318204d9e2.
4
Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure.CYP1A1/CYP1A2 和 AHR 多态性对奥氮平系统暴露的影响。
Pharmacogenet Genomics. 2013 May;23(5):279-85. doi: 10.1097/FPC.0b013e3283602876.
5
Effects of Age, Sex, and Comedication on the Plasma Concentrations of Olanzapine in Chinese Patients With Schizophrenia Based on Therapeutic Drug Monitoring Data.基于治疗药物监测数据的年龄、性别和合并用药对中国精神分裂症患者奥氮平血药浓度的影响。
J Clin Psychopharmacol. 2022;42(6):552-559. doi: 10.1097/JCP.0000000000001618. Epub 2022 Oct 25.
6
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.遗传药理学和奥氮平治疗：CYP1A2*1F 和 5-羟色胺能多态性影响治疗效果。
Pharmacogenomics J. 2010 Feb;10(1):20-9. doi: 10.1038/tpj.2009.32. Epub 2009 Jul 28.
7
Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia.奥氮平及其 N-去甲基代谢产物在精神分裂症住院患者体内的血药浓度与剂量、年龄、性别、体重和吸烟状况的相关性研究。
J Clin Psychopharmacol. 2021;41(3):255-259. doi: 10.1097/JCP.0000000000001390.
8
Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia.精神分裂症患者血浆奥氮平与去甲基奥氮平浓度和代谢参数之间的关系
Front Psychiatry. 2022 Jun 21;13:930457. doi: 10.3389/fpsyt.2022.930457. eCollection 2022.
9
CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy.CYP1A2基因分型影响癫痫患儿卡马西平的药代动力学。
Eur J Clin Pharmacol. 2016 Apr;72(4):439-45. doi: 10.1007/s00228-015-2006-9. Epub 2016 Jan 14.
10
CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients.CYP1A2 表达而非基因型与精神科患者奥氮平浓度相关。
Sci Rep. 2023 Oct 28;13(1):18507. doi: 10.1038/s41598-023-45752-6.

本文引用的文献

1
An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS).对精神分裂症中常用的五种症状评定量表（阳性和阴性症状量表、简明精神病评定量表、阴性症状评定量表、NSA - 16、临床总体印象 - 精神分裂症）的评估及与新量表（临床衰退评估量表、简明阴性症状量表）的比较
J Addict Res Ther. 2017;8(3). doi: 10.4172/2155-6105.1000324. Epub 2017 May 11.
2
Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis.氯氮平治疗难治性精神分裂症的反应率：系统评价和荟萃分析的数据。
Can J Psychiatry. 2017 Nov;62(11):772-777. doi: 10.1177/0706743717718167. Epub 2017 Jun 28.
3
Pharmacogenetics of olanzapine metabolism.
奥氮平代谢的药物遗传学。
Pharmacogenomics. 2013 Aug;14(11):1319-36. doi: 10.2217/pgs.13.120.
4
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.15 种抗精神分裂症药物的疗效和耐受性比较：一项多治疗荟萃分析。
Lancet. 2013 Sep 14;382(9896):951-62. doi: 10.1016/S0140-6736(13)60733-3. Epub 2013 Jun 27.
5
Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009.奥氮平血药浓度与处方剂量及其他因素的关系：来自治疗药物监测服务的数据，1999-2009 年。
J Clin Psychopharmacol. 2011 Aug;31(4):411-7. doi: 10.1097/JCP.0b013e318221b408.
6
High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.精神分裂症或分裂情感性障碍患者服用奥氮平作为唯一抗精神病药物时，血清和脑脊液中奥氮平浓度具有高度相关性。
J Clin Psychopharmacol. 2011 Feb;31(1):4-9. doi: 10.1097/JCP.0b013e318204d9e2.
7
Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients.UGT1A4 142T>G 基因变异携带者易出现奥氮平暴露减少——这种影响类似于精神分裂症患者中的男性性别或吸烟。
Eur J Clin Pharmacol. 2010 May;66(5):465-74. doi: 10.1007/s00228-009-0783-8. Epub 2010 Feb 9.
8
Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.非典型抗精神病药物的体重增加和代谢副作用是否存在剂量依赖性？文献综述。
J Clin Psychiatry. 2009 Jul;70(7):1041-50. doi: 10.4088/jcp.08r04392.
9
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.遗传药理学和奥氮平治疗：CYP1A2*1F 和 5-羟色胺能多态性影响治疗效果。
Pharmacogenomics J. 2010 Feb;10(1):20-9. doi: 10.1038/tpj.2009.32. Epub 2009 Jul 28.
10
Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms.细胞色素P450 1A2（CYP1A2）活性的变异及其临床意义：环境因素和基因多态性的影响
Pharmacogenomics. 2008 May;9(5):625-37. doi: 10.2217/14622416.9.5.625.